AstraZeneca Delays BTG's CytoFab To 2015
29th Jul 2010 17:48
LONDON (Dow Jones)--U.K. drug maker AstraZeneca PLC (AZN.LN) Thursday said it will file an experimental sepsis treatment licensed from BTG PLC (BGC.LN) for marketing approval later than previously expected. The Anglo-Swedish drug maker said in a pipeline update released with its second-quarter r
Read moreLondon close: US gloom offsets company cheer
29th Jul 2010 16:33
Footsie closed slightly in the red, despite starting well on the back of well-received company updates, as weakness in the US spread across the Atlantic. AstraZeneca closed sharply higher. The group's potential blockbuster heart drug Brilinta has received the backing of a US advisory panel just as
Read moreMARKET TALK: FinnCap Cuts BTG To Hold On CytoFab Delay
29th Jul 2010 15:17
1417 GMT [Dow Jones] FinnCap downgrades BTG PLC (BGC.LN) to hold from buy after AstraZeneca PLC (AZN.LN) puts back development of sepsis treatment CytoFab by a year. AstraZeneca says Thursday it expects to file CytoFab for marketing approval in 2015. It previously said it would be filed in 2014, say
Read moreUK MARKET TALK ROUNDUP: SHARES GAINING
29th Jul 2010 15:17
Stocks on the rise in the UK today. Compiled by Dow Jones Newswires Markets Desk, [email protected] Contact us in London. +44-20-7842-9464 [email protected] 1417 GMT [Dow Jones] FinnCap downgrades BTG PLC (BGC.LN) to hold from buy after AstraZeneca PLC (AZN.LN) puts back develop
Read moreMARKET TALK: Double Whammy For Eli Lilly
29th Jul 2010 14:40
9:40 (Dow Jones) It was a double-whammy day for drug maker Eli Lilly (LLY) yesterday. First a US appeals court upheld decision overturning patent for LLY cancer drug Gemzar, which means generic competition could begin later this year. Then FDA advisory committee backed AstraZeneca's (AZN) anti-clott
Read moreFTSE 100 movers: Results push market higher
29th Jul 2010 14:30
A raft of good results has boosted Footsie today. Scientific journals and magazines publisher Reed Elsevier says advertising and promotion markets are stabilising as underlying revenues increased 1% in the first half. AstraZeneca's potential blockbuster heart drug Brilinta has received the backi
Read moreLondon afternoon: Footsie off the top
29th Jul 2010 14:28
The Footsie drifted lower over the lunch time session though still remained in positive territory, thanks in large part to enthusiastic responses to results from heavy hitters AstraZeneca, BT and Reed Elsevier. AstraZeneca is sharply higher. The group's potential blockbuster heart drug Brilinta has
Read moreBEFORE THE BELL: US Stock Futures Rise On Strong Earnings Data
29th Jul 2010 13:06
By Polya Lesova Stock futures pointed to opening gains on Wall Street Thursday, as strong earnings reports from European companies buoyed sentiment, with traders awaiting results from oil major Exxon Mobil Corp. and data on U.S. weekly jobless claims. Futures on the Dow Jones Industrial Ave
Read moreLondon midday: PartyGaming jumps on bwin merger
29th Jul 2010 11:57
Company results have given traders plenty to ponder and shares are broadly higher, but online betting group PartyGaming is the star performer after announcing a merger with Austrian rival bwin. PartyGaming said the merger would create the world's largest listed online gaming business. Elsewhere i
Read moreEuropean midday: Earnings provide lift
29th Jul 2010 11:46
A bunch of forecast beating corporate results are giving Europe's leading exchanges a lift in midday dealings. Across the markets, the Dax in Frankfurt is up 37 points at 6,216, with the Cac in Paris 17 points higher at 3,688. The Swiss market has added 11 points at 6,288. Pharmaceutical firm Merc
Read moreBEFORE THE BELL: US Stock Futures Up Ahead Of Jobless Claims Data
29th Jul 2010 11:14
By Polya Lesova Stock futures pointed to opening gains on Wall Street Thursday, as strong earnings reports from European companies buoyed sentiment, with traders awaiting results from oil major Exxon Mobil Corp. and data on U.S. weekly jobless claims. Futures on the Dow Jones Industrial Ave
Read moreCORRECT: =UPDATE: AstraZeneca Ups Targets, Buybacks
29th Jul 2010 10:00
("=UPDATE: AstraZeneca Ups Targets, Buybacks; Brilinta Hopes Rise" published at 0829 GMT misstated the net profit figure. The same mistake occurred in an item published at 0635 GMT. The correct version follows:) By Sten Stovall Of DOW JONES NEWSWIRES LONDON (Dow Jones)--AstraZeneca PLC
Read moreMARKET TALK: AstraZeneca Soars Post 2Q; Evolution Keeps Sell
29th Jul 2010 09:06
0806 GMT [Dow Jones] AstraZeneca (AZN.LN) shares +4.1% at 3334p, with core 2Q results strong and guidance increased, notes Evolution Securities. Separately, the FDA panel backed broad Brilinta approval, Evolution adds, a positive for the stock. However, Evolution keeps at sell, with a 2850p target.
Read moreUK MARKET TALK ROUNDUP: BROKERS COMMENTS
29th Jul 2010 09:06
Broker comments in the UK today. Compiled by Dow Jones Newswires Markets Desk, [email protected] Contact us in London. +44-20-7842-9464 [email protected] 0806 GMT [Dow Jones] AstraZeneca (AZN.LN) shares +4.1% at 3334p, with core 2Q results strong and guidance increased, notes Ev
Read moreEuropean open: Earnings in focus
29th Jul 2010 09:00
Europe's main markets are cautiously higher in early dealings on Thursday as investors consider a bunch of corporate figures. Across the markets, the Dax in Frankfurt is up 14 points at 6,193, with the Cac in Paris 15 points higher at 3,686. The Swiss market has added 12 points at 6,289. France Te
Read more